Smoking cessation and depression after acute coronary syndrome.

Autor: Krasieva K; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Clair C; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Gencer B; Division of Cardiology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland., Carballo D; Division of Cardiology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland., Klingenberg R; Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Räber L; Department of Cardiology, University Hospital Bern, Bern, Switzerland., Windecker S; Department of Cardiology, University Hospital Bern, Bern, Switzerland., Rodondi N; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland., Matter CM; Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Lüscher TF; Royal Brompton & Harefield Hospital Trust and Imperial College, London SW3 6NP, UK., Mach F; Division of Cardiology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland., Muller O; Service of Cardiology, Lausanne University Hospital, Lausanne, Switzerland., Nanchen D; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland. Electronic address: david.nanchen@unisante.ch.
Jazyk: angličtina
Zdroj: Preventive medicine [Prev Med] 2022 Oct; Vol. 163, pp. 107177. Date of Electronic Publication: 2022 Jul 25.
DOI: 10.1016/j.ypmed.2022.107177
Abstrakt: Smoking and depression are risk factors for acute coronary syndrome (ACS) that often co-exist. We investigated the evolution of depression according to smoking cessation one-year after ACS. Data from 1822 ACS patients of the Swiss multicenter SPUM-ACS cohort study were analyzed over a one-year follow-up. Participants were classified in three groups based on smoking status one-year post-ACS - continuous smokers, smokers who quit within the year, and non-smokers. Depression status at baseline and one-year was assessed with the Center for Epidemiologic Studies Depression scale (CES-D) and antidepressant drug use. A CES-D score ≥ 16 defined depression. A multivariate-adjusted logistic regression model was used to calculate odds ratios (OR) between groups. The study sample mean age was 62.4 years and females represented 20.8%. At baseline, 22.6% were depressed, 40.9% were smokers, and 47.5% of these quit smoking over the year post-ACS. In comparison to depressed continuous smokers, depressed smokers who quit had an adjusted OR 2.59 (95% confidence interval (CI) 1.27-5.25) of going below a CES-D score of 16 or not using antidepressants. New depression at one-year was found in 24.4% of non-depressed smokers who quit, and in 27.1% of non-depressed continuous smokers, with an adjusted OR 0.85 (95% CI 0.55-1.29) of moving to a CES-D score of ≥16 or using antidepressants. In conclusion, smokers with depression at time of ACS who quit smoking improved their depression more frequently compared to continuous smokers. The incidence of new depression among smokers who quit after ACS was similar compared to continuous smokers.
Competing Interests: Declaration of Competing Interest Prof Lüscher reports receiving research grants to the institution from Abbott, Biosensors, Biotronik, Boston Scientific, Daichi Sankyo, Eli Lilly and Medtronic, and consultant payments from AstraZeneca, Boehringer Ingelheim, Bayer, Merck, and Pfizer, MSD, Roche and Servier. Prof Matter reports receiving grants from MSD, Eli Lilly, AstraZeneca, Roche and Bayer; expert testimony from MSD; payment for lectures from MSD, AstraZeneca, and Roche; and having patents from Mabimmune, CH. Prof Windecker reports receiving research contracts to the institution from Abbott, Biotronik, Boston Scientific, Biosensors, Cordis, Medtronic, St. Jude Medical. Prof Mach has received honoraria for advisory boards and conferences on dyslipidaemia from Amgen, AstraZeneca, BMS, Eli Lilly, MSD, Sanofi, and Pfizer. All other authors report no conflicts of interest.
(Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: